# Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

> **NCT00901901** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 732 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)
- **DRUG:** Erlotinib (Tarceva)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00901901
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05-21
- **Primary completion:** 2012-04-17
- **Final completion:** 2018-05-23
- **Target enrollment:** 732 (ACTUAL)
- **Last updated:** 2019-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00901901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00901901, "Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00901901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*